Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

Statistically Significant Data from Phase 2 Study Support Safety and Efficacy of Once Daily Dosing of NK-1 Antagonist, VPD-737 (serlopitant)

South San Francisco, – December 17, 2014

Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant), for the treatment of patients with severe, chronic itch who are unresponsive or inadequately responsive to the current standard of care, including topical steroids and antihistamines.

The primary efficacy endpoint was percent change in Visual Analog Scale (VAS) itch score from baseline, comparing drug to placebo for each dose group. Statistically significant reduction in VAS scores were seen in both the 1mg and 5mg dose groups. The response was durable over the entire treatment period.
VPD-737 is safe and well tolerated.

Gil Yosipovitch, M.D, Professor Chair of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, a principal investigator for the Phase 2 study remarked: "Today is an important day for patients who suffer from severe, chronic pruritus. The results of this study give tremendous hope for the millions of patients who suffer from this debilitating condition, which erodes their quality of life. I look forward to the further development of VPD-737 and hopefully adding it to the treatment armamentarium for patients suffering from intractable pruritus."

Edward Schnipper, M.D., a Founder and Chief Medical Officer at Tigercat Pharma, Inc. remarked: "We are very pleased with the conduct and outcome of this study. We are continuing development of this drug for patients who desperately need a treatment regimen more efficacious than the current standard of care."